Molecular mechanisms of action of ribavirin

Reviews of Infectious Diseases

Volumn 12, Issue 6, 1990, Pages 1139-1146

  Patterson, Jean L ^a,b   Fernandez Larsson, Roberto ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ANTIVIRAL ACTIVITY; HANTAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFLUENZA VIRUS; LASSA VIRUS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION;

BUNYAVIRIDAE; DNA VIRUSES; DNA-DIRECTED RNA POLYMERASES; HUMAN; NUCLEOTIDES; RIBAVIRIN; RNA, MESSENGER; RNA, VIRAL; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025203460     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/12.6.1139     Document Type: Article

References (40)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: l-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;177:705–6
2. McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet 1984;2:1367–9
3. Vogt MW, Hartshorn KL, Furman PA, Chou T-C, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT, Hirsch MS. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376–9
4. Malinoski F, Stollar V. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication andTeduce GTP levels in Aedes albopictus cells. Virology 1981;110:281–91
5. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1–β- D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174–8
6. Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 1979;89: 830–6
7. Smith RA. Background and mechanisms of action of ribavirin. In: Smith RA, Knight V, Smith JAD, eds. Clinical applications of actions of ribavirin. New York: Academic Press, 1984:1–18
8. Sidwell RW. In vitro and in vivo inhibition of DNA viruses by ribavirin. In Smith RA, Knight V, Smith JAD, eds. Clinical application of actions of ribavirin. New York: Academic Press, 1984;19–32
9. Prusiner P, Sundaralingam M. A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties. Nature [New Biol] 1973;244:116–8
10. Katz E, Margalith E, Winer B. Inhibition of vaccinia virus growth by the nucleoside analogue 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ribavirin). J Gen Virol 1976;32:327–30
11. Canonico PG, Little JS, Jahrling PB, Stephen EL. Molecular aspects of the antiviral activity of ribavirin on Venezuelan equine encephalomyelitis virus. In: Nelson JD, Grassi C, eds. Current chemotherapy and infectious disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol. 2. Washington DC: American Society for Microbiology, 1980:1370–2
12. Toltzis P, Huang AS. Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. Antimicrob Agents Chemother 1986;29:1010–6
13. Rankin JT Jr, Eppes SB, Antczak JB, Joklik WK. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 1989;168:147–58
14. Ehrenfeld E. Poliovirus-induced inhibition of host-cell protein synthesis. Cell 1982;28:435–6
15. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;ll(Suppl 4):S750–61
16. Cassidy LF, Patterson JL. Mechanism of La Crosse virus in hibition by ribavirin. Antimicrob Agents Chemother 1989;33:2009–11
17. Porterfield JS, Casals J, Chumakov MP, Gaidamovich SY, Hannoun C, Holmer IH, Horzinek MC, Mussgay M, Oker- blom N, Russell PK. Bunyaviruses and Bunyaviridae. Intervirology 1976;6:13–4
18. Obijeski JF, Bishop D.H.L., Murphy FA, Palmer EL. Structural proteins of La Crosse virus. J Virol 1976;19:985–97
19. Krug RM. Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr Tbp Microbiol Immunol 1981;93:125–49
20. Patterson JL, Holloway B, Kolakofsky D. LaCrosse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. J Virol 1984;52:215–22
21. Sidwell RW, Huffman JH, Barnett BB, Pifat DY. In vitro and in vivo phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 1988;32:331–6
22. Leppert M, Rittenhous L, Perrault J, Summers DF, Kolakofsky D. Plus and minus strand leader RNAs in negative strand virus-infected cells. Cell 1979;18:735–47
23. Patterson JL, Kolakofsky D. Characterization of LaCrosse virus small genome transcripts. J Virol 1984;49:680–5
24. Kolakofsky D, Bellocq C, Raju R. The translational requirement for LaCrosse virus S-mRNA synthesis. Cold Spring Harb Symp Quant Biol 1987;52:373–9
25. Ferrara EA, Oishi JS, Wannemacher RW Jr, Stephen EL, Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother 1981;19:1042–9
26. Crumpacker C, Bubley G, Lucey D, Hussey S, Connor J. Ribavirin enters cerebrospinal fluid. Lancet 1986;2:45–6
27. Ogle JW, Toltzis P, Parker WD, Alvarez N, McIntosh K, Levin MJ, Lauer BA. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis 1989;159:748–50
28. Wray SK, Gilbert BE, Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 1985; 5:39–48
29. Toltzis P, O’Connell K, Patterson JL, Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob Agents Chemother 1988;32:492–7
30. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977;11:946–51
31. Furman PA, St. Clair MH, Spector T, Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984;259:9575–9
32. Fernandez-Larsson R, O’Connell K, Koumans E, Patterson JL, Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob Agents Chemother 1989;33:1668–73
33. Lachenmann MJ, Fernandez-Larsson R, Patterson JL. Stabilized Ribavirin diphosphate analogs inhibit the vesicular stomatitis virus (Indiana) in vitro transcription reaction. Arch Virol 1990 (in press)
34. Fernandez-Larsson R, Patterson JL. Altered ATP function of a vesicular stomatitis virus mutant detected by kinetic analysis of the transcriptase using phosphorylated ribavirin. J Gen Virol 1989;70:2791–7
35. Shope R. Bunyaviruses. In: Fields B, ed. Fields virology. New York: Raven Press, 1984:1055–82
36. Tsai TF, Bauer SP, Sasso DR, Whitfield SG, McCormick JB, Caraway TC, McFarland L, Bradford H, Kurata T. Serological and virological evidence of a Hantaan virus-related enzootic in the United States. J Infect Dis 1985;152:126–36
37. Childs JE, Glass GE, Korch GW, Arthur RR, Shah KV, Glasser D, Rossi C, LeDuc JW. Evidence of human infection with a rat-associated Hantavirus in Baltimore, Maryland. Am J Epidemiol 1988;127:875–8
38. Yanagihara R, Gajdusek DC. In: Gear JHS, ed. Handbook of viral and rickettsial hemorrhagic fevers. Hemorrhagic fever with renal syndrome: historical perspective and review of recent advances. Boca Raton, Fla: CRC Press, 1988:155–81
39. Lee HW, Lee PW, Baek LJ, Song CK, Seong IW. Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever, in the rodent Apodemus agrarius. Am J Trop Med Hyg 1981;30:1106–12
40. Huggins JW, Kim GR, Brand OM, McKee KT Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 1986;153:489–97